VAPONEFRIN 2.25 %
RACEMIC EPINEPHRINE HYDROCHLORIDE : 2.25 % · DIN 01927582 · SANOFI-AVENTIS CANADA INC
Health Canada status: CANCELLED POST MARKET
What is VAPONEFRIN?
VAPONEFRIN 2.25 % contains RACEMIC EPINEPHRINE HYDROCHLORIDE : 2.25 %. It is listed in the Health Canada Drug Product Database under DIN 01927582, held by SANOFI-AVENTIS CANADA INC, supplied as SOLUTION for INHALATION administration. Health Canada currently lists it as cancelled post market, status dated 31-Jul-2007. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 01927582 |
|---|---|
| Brand name | VAPONEFRIN |
| Generic / active ingredient | RACEMIC EPINEPHRINE HYDROCHLORIDE : 2.25 % |
| Manufacturer | SANOFI-AVENTIS CANADA INC |
| Strength | 2.25 % |
| Dosage form | SOLUTION |
| Route of administration | INHALATION |
| Schedule | Ethical |
| ATC code | R03AA01 EPINEPHRINE |
| AHFS class | 12:12.12 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 31-Jul-2007 |
| Original market date | 1992-12-31 00:00:00 |
How is this product identified?
Purchase orders, customs paperwork and tender documents each ask for a different identifier, and a DIN written without its leading zeros is the single most common reason an order line fails to match. Every form Nexara accepts for this product is listed here.
| DIN (8-digit, as used in Nexara ordering) | 01927582 |
|---|---|
| DIN (unpadded, as printed on some documents) | 1927582 |
| Brand name | VAPONEFRIN |
| Active ingredient / INN | RACEMIC EPINEPHRINE HYDROCHLORIDE : 2.25 % |
| ATC code | R03AA01 |
| ATC anatomical main group | R — Respiratory system |
| ATC therapeutic subgroup | R03 |
| AHFS class | 12:12.12 |
| Health Canada schedule | Ethical |
| Biosimilar biologic | No |
| Market authorization holder | SANOFI-AVENTIS CANADA INC |
Which pack is which?
| Strength on the label | 2.25 % |
|---|---|
| Dosage form | SOLUTION |
| Route | INHALATION |
One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced. Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Is EPINEPHRINE in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Active — reported by PFIZER CANADA ULC, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code R03AA01 EPINEPHRINE. 0 of 4 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| BRONKAID MISTOMETER AEM 0.5% | 0.5 % | METERED-DOSE AEROSOL | SANOFI CANADA, INC. | CANCELLED POST MARKET | DIN 02017555 |
| DYSNE INHAL | 3.5 % | SPRAY | ROUGIER PHARMA DIVISION OF RATIOPHARM INC | CANCELLED POST MARKET | DIN 00466417 |
| S2 | 2.25 % | SOLUTION | NEPHRON PHARMACEUTICALS CORPORATION | CANCELLED POST MARKET | DIN 00525103 |
How much does EPINEPHRINE cost around the world?
EPINEPHRINE is listed on 6 national price registers Nexara tracks, across 32 pack listings published on 6 different price bases. What each country publishes is set out below.
| Market | What that country publishes | Brands listed | Pack listings | As of |
|---|---|---|---|---|
| United States | acquisition | 3 | 13 | 03 Sep 2026 |
| Saudi Arabia | public | 7 | 7 | 01 Sep 2026 |
| Morocco | PPV (public price) | 3 | 6 | 05 Sep 2026 |
| Greece | producer price (ex-factory) | 4 | 4 | 03 Sep 2026 |
| Bahrain | retail (max) | 1 | 1 | 01 Sep 2026 |
| South Africa | single exit price | 1 | 1 | 01 Sep 2026 |
Why there are no figures here. These bases are not comparable. A Brazilian ex-factory ceiling, a Belgian pharmacy public price and a Japanese reimbursement rate answer three different questions, and none of them is what a product lands in Canada for. Putting them side by side would mislead in both directions, so Nexara publishes where a molecule is listed and on what basis, and quotes the delivered Canadian price per order.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.